Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shire establishes U.S. headquarters

Executive Summary

U.K.-based Shire sets up North American headquarters in Wayne, Penn. and plans to close its facilities in Rockville, Md. and Newport, Ky. The new facility will house about 400 employees by end of 2005. Establishing a U.S. headquarters was one step in a streamlining effort announced by CEO Matthew Emmens shortly after he joined the company this spring (1"The Pink Sheet" March 17, 2004, In Brief)...

You may also be interested in...



Shire hires ex-Merck exec

Former Merck KGaA global ethical pharmaceuticals president Matthew Emmens named CEO of Shire effective March 19. Emmens succeeds Rolf Stahel, who announced his intention to leave the company in October. Emmens previously spent 19 years at U.S. Merck & Co., and was CEO of Astra Merck joint venture...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel